Preview

Siberian journal of oncology

Advanced search

STUDY OF THE RELATIONSHIP BETWEEN KRAS GENE MUTATIONS AND GENDER, AGE AND RACE IN COLORECTAL CANCER PATIENTS RESIDING IN THE REPUBLIC OF KAZAKHSTAN

https://doi.org/10.21294/1814-4861-2020-19-1-82-89

Abstract

In 2016 3158 patients with colorectal cancer (CRC) were registered in the Republic of Kazakhstan, out of them, 1,484 patients died. Colorectal and colon cancers are the 8th and the 5th leading causes of mortality, respectively. One of the most significant events in the molecular pathogenesis of CRC is an activating mutation in the KRAS oncogene. Recently, studies of the KRAS gene mutation and analysis of its relation with the clinical course of CRC have been carried out in different countries. The effect of gender and age on the KRAS gene status in CRC remains a subject for discussion.

The purpose of this study was to study the relationship between the KRAS gene status and gender, age and race in colorectal cancer patients residing in the Republic of Kazakhstan.

Material and methods. Data on 332 patients with CRC for the period from 2010 to 2014 were studied. KRAS test was performed using BioLink kits to detect mutations in 12 and 13 codons of 2 exon using allele-specific PCR method.

Results. In our study, the frequency of KRAS gene mutations in CRC patients residing in the Republic of Kazakhstan was 44.9 %. The frequency of mutations in the studied codons among women and men was the same. When analyzing the mutation frequency of the KRAS gene, it was revealed that among both sexes the G12D mutation was more often observed. The least common mutations were G12C, G12S, which occurred in both sexes (up to 5 % of cases). The analysis of the dependence of the mutation on the race of the patients revealed some predominance of the wild type in the Asian group – 94 (51.4 %), while Europeans were more often detected with the KRAS mutation – in 81 (54.4 %) patients. Mutation of the KRAS gene was more frequently observed in the group of older patients.

About the Authors

D. R. Kaydarova
Kazakh Research Institute of Oncology and Radiology
Kazakhstan

MD

Author ID (Scopus): 55263578700

91, Abaya avenue, Almaty, 050000, Kazakhstan





K. K. Smagulova
Kazakh Research Institute of Oncology and Radiology
Kazakhstan
MD, PhD, Head of the Chemotherapy Department

91, Abaya avenue, Almaty, 050000, Kazakhstan



N. A. Chichua
Kazakh Research Institute of Oncology and Radiology
Kazakhstan
MD, DSc, Professor, Physician at the Chemotherapy Department

91, Abaya avenue, Almaty, 050000, Kazakhstan



E. A. Ukolova
Kazakh Research Institute of Oncology and Radiology
Kazakhstan
MD, Physician at the Chemotherapy Department

91, Abaya avenue, Almaty, 050000, Kazakhstan



A. Z. Kurmankulova
Kazakh Research Institute of Oncology and Radiology
Kazakhstan
MD, Physician at the Chemotherapy Department

91, Abaya avenue, Almaty, 050000, Kazakhstan



E. I. Ishkinin
Kazakh Research Institute of Oncology and Radiology
Kazakhstan
MD, Researcher

91, Abaya avenue, Almaty, 050000, Kazakhstan



References

1. World Health Organization. International agency for research on Cancer. GLOBOCAN 2012 [Internet]. URL: https://www.iarc.fr/group‑publication/cancer‑incidence‑and‑mortality‑worldwide‑sources‑methods‑and‑major‑patterns‑in‑globocan‑2012 (cited 11.04.2019).

2. Kaidarova D.R., Auezova E.T., Chingisova Zh.K., Seisenbaeva G.T., Azhmagambetova A.E., Zhylkaidarova A.Zh. Indicators of the Oncological Service of the Republic of Kazakhstan for 2016 (statistical materials). Almaty, 2017. 170 c. (in Russian).

3. Van Cutsem E., Siena S., Freeman D.J., Juan T., Sikorski R., Suggs S., Radinsky R., Patterson S.D., Chang D.D. Wild‑type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008 Apr 1; 26(10): 1626–34. doi: 10.1200/JCO.2007.14.7116.

4. Breivik J., Meling G.I., Spurkland A., Rognum T.O., Gaudernack G. K‑ras mutation in colorectal cancer: relations to patient age, sex and tumour location. Br J Cancer. 1994 Feb; 69(2): 367–71. doi: 10.1038/bjc.1994.67.

5. Arber N., Shapira I., Ratan J., Stern B., Hibshoosh H., Moshkowitz M., Gammon M., Fabian I., Halpern Z. Activation of c‑K‑ras mutations in human gastrointestinal tumors. Gastroenterology. 2000 Jun; 118(6): 1045–50. doi: 10.1016/s0016‑5085(00)70357‑x.

6. Jakovljevic K., Malisic E., Cavic M., Krivokuca A., Dobricic J., Jankovic R. KRAS and BRAF mutations in Serbian patients with colorectal cancer. J BUON. 2012 Jul‑Sep; 17(3): 575–80.

7. Wang D., Liang W., Duan X., Liu L., Shen H., Peng Y., Li B. Detection of KRAS gene mutations in colorectal carcinoma: a study of 6 364 patients. Zhonghua Bing Li Xue Za Zhi. 2014 Sep; 43(9): 583–7.


Review

For citations:


Kaydarova D.R., Smagulova K.K., Chichua N.A., Ukolova E.A., Kurmankulova A.Z., Ishkinin E.I. STUDY OF THE RELATIONSHIP BETWEEN KRAS GENE MUTATIONS AND GENDER, AGE AND RACE IN COLORECTAL CANCER PATIENTS RESIDING IN THE REPUBLIC OF KAZAKHSTAN. Siberian journal of oncology. 2020;19(1):82-89. (In Russ.) https://doi.org/10.21294/1814-4861-2020-19-1-82-89

Views: 948


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1814-4861 (Print)
ISSN 2312-3168 (Online)